期刊
INTERNATIONAL UROGYNECOLOGY JOURNAL
卷 19, 期 11, 页码 1551-1557出版社
SPRINGER LONDON LTD
DOI: 10.1007/s00192-008-0688-6
关键词
anxiety; Overactive bladder; sexual health; urgency urinary incontinence; women
资金
- Pfizer Inc. ClinicalTrials. gov identifier [NCT00143481]
We evaluated overactive bladder (OAB) symptoms and sexual and emotional health in sexually active women with OAB/urgency urinary incontinence (UUI) treated with tolterodine extended release (ER). Sexually active women with OAB symptoms were randomized to placebo or tolterodine ER. Five-day bladder diaries, Sexual Quality of Life Questionnaire-Female (SQOL-F), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), and Hospital Anxiety and Depression Scale (HAD) were completed at baseline and week 12. Tolterodine ER (n=201; mean +/- SD age, 49 +/- 12 years) reduced UUI episodes (P=0.0029), total (P=0.0006) and OAB (P < 0.0001) micturitions, and pad use per 24 h (P=0.0024), and was associated with improvements in SQOL-F (P=0.004), PISQ total (P=0.009), and HAD Anxiety (P=0.03) scores versus placebo (n=210; mean +/- SD age, 47 +/- 12 years). OAB symptoms improved with tolterodine ER as did the scores of sexual health and anxiety measures in sexually active women with OAB.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据